Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

by Jill Wechsler Manufacturers are concerned about congressional efforts to establish a Medicare pharmacy benefit and to regulate research while FDA shifts regulation of biologics and other drugs.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 23 years ago

Article

Virus Inactivation in the 1990s and into the 21st Century: Part 4, Culture Media, Biotechnology Products, and Vaccines

almost 23 years ago

Article

Biotech World: Canada's Supreme Court says "No" to Harvard Mouse

almost 23 years ago

Article

Rethinking the Economics of Chromatography: New Technologies and Hidden Costs

almost 23 years ago

Article

Outsourcing Outlook: Using Virtual Private Networks to Gain Competitive Advantage

almost 23 years ago

Article

Employing Near-Infrared Spectroscopic Methods of Analysis for Fermentation Monitoring and Control: Part 2, Implementation Strategies

almost 23 years ago

Article

Guest Editorial: At the Governance Crossroad

almost 23 years ago

Article

Reducing Costs by Facility Design

almost 23 years ago

Article

Guidelines for Optimization and Scale-Up in Preparative Chromatography

almost 23 years ago

Article

Analytical Advances: Funneling a Flood Tide of Data ? New Software Accelerates Bioinformatic Analyses

almost 23 years ago

Article

Survival Strategies: Board Compensation Changing with the Times

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Inside Washington: Coverage and Consolidation ? Key Issues for Biotech Companies

Articles in this issue

Newsletter